Hydrolysis of mannose-1-phospho-6-mannose linkage to phospho-6-mannose
Described herein are methods and genetically engineered cells useful for uncapping a mannose-6-phosphate residue on an oligosaccharide.
1. A method for uncapping a mannose-6-phosphate residue on an oligosaccharide, said method comprising
a) providing said oligosaccharide having a mannose-1-phospho-6-mannose linkage; and
b) contacting said oligosaccharide with a mannosidase capable of hydrolyzing said mannose-1-phospho-6-mannose residue to phospho-6-mannose, wherein said mannosidase is a member of glycosyl hydrolase family 92, wherein said mannosidase comprises an amino acid sequence having at least 95% identity to residues 1 to 774 of SEQ ID NO:50 or at least 98% identity to SEQ ID NO:50.
2. The method of claim 1 , wherein said mannosidase comprises an amino acid sequence having at least 98% identity to residues 1 to 774 of SEQ ID NO:50.
3. The method of claim 1 , wherein said amino acid sequence comprises residues 1-774 of SEQ ID NO:50 or SEQ ID NO:50.
4. The method of claim 3 , wherein said amino acid sequence further comprises, N-terminal of residues 1-774 of SEQ ID NO:50 or of SEQ ID NO:50, residues 1-15 of SEQ ID NO:15.
5. The method of claim 1 , wherein for said mannosidase, the three dimensional protein coordinates of the atoms in the amino acid side chains located in the minimal catalytic center fall within 1.5 Å deviation of the coordinates of the equivalent atoms in FIG. 33 .
6. The method of claim 1 , wherein said mannosidase comprises an amino acid sequence having (i) a GVGXXGXGG motif, where X is Gly, Ala, Ser, Thr, or Cys; (ii) a VRXE motif, where X is any amino acid other than Pro; (iii) an X 1 YQGX 2 motif, where X 1 is Leu, Ile, Val, Ala, Phe, Tyr or Met, and X 2 is Thr, Ser, or Asn; or (iv) GDXGN, where X can be any amino acid other than Pro.
7. The method of claim 1 , wherein said contacting step is performed using a purified mannosidase, a recombinant mannosidase, a cell lysate containing said recombinant mannosidase, or a fungal cell containing said recombinant mannosidase.
8. The method of claim 1 , wherein said oligosaccharide is attached to a protein.
9. The method of claim 8 , wherein said protein is a human protein expressed in a fungal organism.
10. The method of claim 9 , wherein said fungal organism is Yarrowia lipolytica or Arxula adeninivorans.
11. The method of claim 9 , wherein said fungal organism is a methylotrophic yeast.
12. The method of claim 11 , wherein said methylotrophic yeast is Pichia pastoris, Pichia methanolica, Oogataea minuta, or Hansenula polymorpha.
13. The method of claim 9 , wherein said fungal organism is a filamentous fungus.
14. The method of claim 13 , wherein said filamentous fungus is selected from the group consisting of Aspergillus caesiellus, Aspergillus candidus, Aspergillus carneus, Aspergillus clavatus, Aspergillus deflectus, Aspergillus flavus, Aspergillus fumigatus, Aspergillus glaucus, Aspergillus nidulans, Aspergillus niger, Aspergillus ochraceus, Aspergillus oryzae, Aspergillus parasiticus, Aspergillus penicilloides, Aspergillus restrictus, Aspergillus sojae, Aspergillus sydowi, Aspergillus tamari, Aspergillus terreus, Aspergillus ustus, and Aspergillus versicolor.
15. The method of claim 8 , wherein said protein is a pathogen protein, a lysosomal protein, a growth factor, a cytokine, a chemokine, an antibody or antigen-binding fragment thereof, or a fusion protein.
16. The method of claim 15 , wherein said lysosomal protein is a lysosomal enzyme.
17. The method of claim 16 , wherein said lysosomal enzyme is associated with a lysosomal storage disorder (LSD).
18. The method of claim 17 , wherein said LSD is Fabry's disease, mucopolysaccharidosis I, Farber disease, Gaucher disease, GM1-gangliosidosis, Tay-Sachs disease, Sandhoff disease, GM2 activator disease, Krabbe disease, metachromatic leukodystrophy, Niemann-Pick disease, Scheie disease, Hunter disease, Sanfilippo disease, Morquio disease, Maroteaux-Lamy disease, hyaluronidase deficiency, aspartylglucosaminuria, fucosidosis, mannosidosis, Schindler disease, sialidosis type 1, Pompe disease, Pycnodysostosis, ceroid lipofuscinosis, cholesterol ester storage disease, Wolman disease, Multiple sulfatase deficiency, galactosialidosis, mucolipidosis, cystinosis, sialic acid storage disorder, chylomicron retention disease with Marinesco-Sjögren syndrome, Hermansky-Pudlak syndrome, Chediak-Higashi syndrome, Danon disease, or Geleophysic dysplasia.
19. The method of claim 17 , wherein said LSD is Pompe disease or Fabry's disease.
20. The method of claim 1 , wherein said mannosidase comprises a targeting signal to target said mannosidase to an intracellular compartment.
21. The method of claim 1 , wherein the mannosidase is:
(a) a deletion variant that is the polypeptide consisting of residues 1 to 774 of SEQ ID NO:50 or consisting of SEQ ID NO:50, but lacks up to ten amino acid segments, each segment consisting of one or two amino acids; or
(b) a substitution variant that is:
(i) the polypeptide consisting of residues 1 to 774 of SEQ ID NO:50 or consisting of SEQ ID NO:50; or
(ii) the variant of (a);
but with no more than 10 conservative substitutions.